

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-21. (Canceled)

22. (Currently amended) A method of treating a patient who is suffering from ~~a disease or condition associated with undesirable muscle contraction that results from~~ exaggerated release of acetylcholine from presynaptic nerve terminals, the method comprising administering to the patient a therapeutically effective amount of a composition comprising a substantially pure polypeptide complex comprising a Clostridium botulinum neurotoxin and one or more Clostridium botulinum type E neurotoxin associated ~~polypeptide~~ polypeptides selected from the group consisting of a polypeptide comprising the amino acid sequence of SEQ ID NO:4, a polypeptide comprising the amino acid sequence of SEQ ID NO:3, a polypeptide comprising the amino acid sequence of SEQ ID NO:2, a polypeptide comprising the amino acid sequence of SEQ ID NO:1, and a polypeptide comprising the amino acid sequence of SEQ ID NO:5, wherein the composition is administered in an amount sufficient to reduce acetylcholine release from presynaptic nerve terminals.

23. (Cancelled).

24. (Currently amended) ~~The method of claim 22, wherein the excessive release of acetylcholine causes profuse sweating, lacrimation, or mucous secretion. A method of treating a patient who is suffering from sweating, lacrimation, or mucous secretion that result from exaggerated release of acetylcholine from presynaptic nerve terminals, the method comprising administering to the patient a therapeutically effective amount of a composition comprising a~~

substantially pure polypeptide complex comprising a Clostridium botulinum neurotoxin and one or more Clostridium botulinum type E neurotoxin associated polypeptide polypeptides selected from the group consisting of a polypeptide comprising the amino acid sequence of SEQ ID NO:4, a polypeptide comprising the amino acid sequence of SEQ ID NO:3, a polypeptide comprising the amino acid sequence of SEQ ID NO:2, a polypeptide comprising the amino acid sequence of SEQ ID NO:1, and a polypeptide comprising the amino acid sequence of SEQ ID NO:5, wherein the composition is administered in an amount sufficient to reduce acetylcholine release from presynaptic nerve terminals.

25-32. (Canceled)

33. (Previously presented) The method of claim 22, wherein the neurotoxin associated polypeptide comprises the amino acid sequence of SEQ ID NO:4.

34. (Previously presented) The method of claim 22, wherein the neurotoxin associated polypeptide comprises the amino acid sequence of SEQ ID NO:3.

35. (Previously presented) The method of claim 22, wherein the neurotoxin associated polypeptide comprises the amino acid sequence of SEQ ID NO:2.

36. (Previously presented) The method of claim 22, wherein the neurotoxin associated polypeptide comprises the amino acid sequence of SEQ ID NO:1.

37. (Previously presented) The method of claim 22, wherein the neurotoxin associated polypeptide comprises the amino acid sequence of SEQ ID NO:5.

38. (New) The method of claim 22, wherein the undesirable muscle contraction is associated with spasmodic torticollis, essential tremor, spasmodic dysphonia, charley horse, strabismus, blepharospasm, oromandibular dystonia, spasms of the sphincters of the cardiovascular, gastrointestinal, or urinary systems, or tardive dyskinesia.

39. (New) The method of claim 22, wherein the undesirable muscle contraction is associated with spasticity occurring secondary to brain ischemia, or traumatic injury of the brain or spinal cord.

40. (New) The method of claim 22, wherein the undesirable muscle contraction is associated with tension headache or pain.

41. (New) The method of claim 24, wherein the neurotoxin associated polypeptide comprises the amino acid sequence of SEQ ID NO:4.

42. (New) The method of claim 24, wherein the neurotoxin associated polypeptide comprises the amino acid sequence of SEQ ID NO:3.

43. (New) The method of claim 24, wherein the neurotoxin associated polypeptide comprises the amino acid sequence of SEQ ID NO:2.

44. (New) The method of claim 24, wherein the neurotoxin associated polypeptide comprises the amino acid sequence of SEQ ID NO:1.

45. (New) The method of claim 24, wherein the neurotoxin associated polypeptide comprises the amino acid sequence of SEQ ID NO:5.